Brainsway Ltd (BWAY)vsJohnson & Johnson (JNJ)
BWAY
Brainsway Ltd
$13.57
-0.29%
HEALTHCARE · Cap: $560.10M
JNJ
Johnson & Johnson
$269.55
-0.19%
HEALTHCARE · Cap: $640.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 161246% more annual revenue ($97.93B vs $60.70M). JNJ leads profitability with a 21.5% profit margin vs 15.6%. JNJ trades at a lower P/E of 30.9x. JNJ earns a higher WallStSmart Score of 59/100 (C).
BWAY
Buy50
out of 100
Grade: C-
JNJ
Buy59
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.4% year-over-year
Earnings expanding 64.6% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Distress zone — elevated risk
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : BWAY
The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 14.0%. Revenue growth of 35.4% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : BWAY
The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 60.6x leaves little room for execution misses.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
BWAY profiles as a growth stock while JNJ is a mature play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.23 — expect wider price swings.
BWAY is growing revenue faster at 35.4% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 50/100), backed by strong 21.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Brainsway Ltd
HEALTHCARE · MEDICAL DEVICES · USA
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?